摘要
目的分析重组人血小板生成素(rh TPO)在血液肿瘤化疗后血小板减少症(CIT)治疗中的应用价值。方法将110例血液肿瘤CIT患者随机分为两组,以接受白细胞介素(IL)-11治疗者为对照组,以接受rh TPO治疗者为观察组,每组55例。分析两组治疗过程中血小板计数(PLT)及相关炎性因子的变化情况。结果治疗前后两组PLT呈先降后升趋势,IL-4及IL-8呈先升后降趋势(P <0.05)。虽然两组入组时及治疗2d后,PLT、IL-4及IL-8比较差异无统计学意义(P>0.05),而治疗7d及14d后,观察组PLT高于对照组,IL-4及IL-8低于对照组,差异有统计学意义(P <0.05)。同时,完全14d治疗后,观察组治疗总有效率高于对照组,差异有统计学意义(P <0.05)。此外,在14d治疗过程中,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论相对于IL-11治疗,rhTPO可更有效的提高血液肿瘤CIT的治疗效果。
Objective To analyze the practical value of the recombinant human thrombopoietin（rhTPO） inthe treatment of thrombocytopenia induced by blood tumor chemotherapy. Methods One hundred and ten patients withthrombocytopenia induced by blood cancer treatment were randomly divided into two groups,with 55 cases in each. Thepatients of control group received only IL-11 treatment and those of observation group were given rhTPO. Platelet count（PLT） and inflammatory cytokines were detected. Results All patients showed a primary PLT decrease followed by anincrease before and after treatments,while IL-4 and IL-8 levels were elevated early and reduced gradually（P 〈0.05）. ThePLT level was found to be increased but IL-4 and IL-8 decreased in observation group after 7 and 1 4 days of treatments（P 〈0.05）. As a result,the total effective rate of the observation group was notably higher than those of the control after 14days of treatments（P 〈0.05）. However,no difference of the adverse reactions was seen between the two groups（P 〉0.05）.Conclusion Compared with IL-1 1,rhTPO is more effective for the treatment of thrombocytopenia caused by leukemiachemotherapy.
作者
孙少勤
SUN Shao-qin(Depatment of Hematology,Hebei Province Dingzhou People＇s Hospital,Dingzhou 07300)
出处
《临床输血与检验》
CAS
2018年第6期632-635,共4页
Journal of Clinical Transfusion and Laboratory Medicine
